CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 1%

CRISPR Therapeutics AG (NASDAQ:CRSP) shares were up 1% during trading on Friday . The stock traded as high as $54.94 and last traded at $54.27. Approximately 375,067 shares were traded during mid-day trading, a decline of 79% from the average daily volume of 1,789,485 shares. The stock had previously closed at $53.73.

Analyst Upgrades and Downgrades

Several analysts have issued reports on CRSP shares. Citigroup raised their price target on shares of CRISPR Therapeutics from $88.00 to $89.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th. Morgan Stanley raised their price target on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the stock an “underweight” rating in a research report on Monday, February 26th. Chardan Capital raised their price target on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. Wolfe Research began coverage on shares of CRISPR Therapeutics in a research report on Thursday, February 15th. They issued a “peer perform” rating on the stock. Finally, Royal Bank of Canada lifted their target price on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the company a “sector perform” rating in a research report on Thursday, February 22nd. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $76.29.

CRISPR Therapeutics Stock Up 0.3 %

The company’s fifty day moving average is $71.13 and its 200 day moving average is $63.73. The firm has a market cap of $4.58 billion, a price-to-earnings ratio of -27.50 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.95. The firm had revenue of $201.20 million for the quarter, compared to the consensus estimate of $148.72 million. During the same period last year, the company posted ($1.41) earnings per share. The business’s revenue was up 3253.3% compared to the same quarter last year. On average, equities research analysts forecast that CRISPR Therapeutics AG will post -6.24 EPS for the current fiscal year.

Insider Activity

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 20,000 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $80.36, for a total transaction of $1,607,200.00. Following the sale, the chief executive officer now directly owns 187,377 shares in the company, valued at $15,057,615.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 20,000 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $80.36, for a total transaction of $1,607,200.00. Following the sale, the chief executive officer now directly owns 187,377 shares in the company, valued at $15,057,615.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, General Counsel James R. Kasinger sold 1,913 shares of the stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total transaction of $152,408.71. Following the sale, the general counsel now owns 57,371 shares in the company, valued at $4,570,747.57. The disclosure for this sale can be found here. Insiders have sold 133,992 shares of company stock valued at $9,157,835 over the last ninety days. 4.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Jump Financial LLC raised its holdings in CRISPR Therapeutics by 194.7% during the 3rd quarter. Jump Financial LLC now owns 33,307 shares of the company’s stock worth $1,512,000 after purchasing an additional 22,006 shares during the last quarter. Capital Advisors Inc. OK increased its stake in shares of CRISPR Therapeutics by 7.4% in the 3rd quarter. Capital Advisors Inc. OK now owns 231,925 shares of the company’s stock valued at $10,527,000 after acquiring an additional 15,951 shares in the last quarter. Invesco Ltd. raised its holdings in CRISPR Therapeutics by 1.5% during the third quarter. Invesco Ltd. now owns 136,123 shares of the company’s stock worth $6,179,000 after buying an additional 2,061 shares during the last quarter. ARK Investment Management LLC raised its holdings in CRISPR Therapeutics by 19.2% during the fourth quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock worth $534,360,000 after buying an additional 1,372,986 shares during the last quarter. Finally, Prime Capital Investment Advisors LLC acquired a new position in CRISPR Therapeutics during the fourth quarter worth $206,000. Institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.